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Take Home Message 
This paper describes the validation process for a new severe asthma specific quality 
of life questionnaire, the SAQ. 
 
 
Abstract  
Background 
The USA’s Food and Drug Administration’s procedure for scale validation requires a 
documented stepwise process of qualitative and quantitative data.  The aim of this 
paper is to provide the final quantitative validating data. 
Methods  
The severe asthma questionnaire (SAQ), asthma control test (ACT), MiniAQLQ, and 
EQ-5D-5L were completed by 160 patients attending a severe asthma clinic; 51 
patients completed the SAQ on two occasions for test-retest reliability analysis. The 
SAQ produces two scores, an SAQ score based on the average of 16 items and a 
SAQ-global score from a single 100-point global quality of life scale. 
Results 
Construct validity was demonstrated through factor analysis of the 16 items, 
convergent validity by correlations of > 0.6 between the SAQ, SAQ-global and other 
questionnaires, and discriminant validity by the ability of the SAQ and SAQ-global to 
distinguish between different treatment levels. Test-retest reliability (intra-class 
correlation) was 0.93 for the SAQ and 0.93 for the SAQ-global, and the alpha 
coefficient for the SAQ was 0.93.  
Conclusions 
The SAQ was developed using recommended qualitative and quantitative 
procedures for scale development, and can be used to gain insight into patients’ 
perceptions of the impact of severe asthma and its treatment on their lives.  
Keywords: Asthma; Outcome; Quality of Life. 
 
 
 
 
Introduction  
Patients with severe and difficult-to-treat asthma comprise a small proportion (5-
10%) of all asthmatic patients, yet are responsible for a disproportionate degree of 
asthma morbidity and costs [1,2]. Quality of life assessment forms an essential part 
of asthma assessment as measures such as respiratory symptoms and lung function 
may not convey the true limitations caused by the disease from the patient’s 
perspective [3]. Compared to mild and moderate asthma, patients with severe 
asthma have additional quality of life deficits caused by multiple and more severe 
exacerbations that disrupt the lives of patients and their relatives, comorbidities, and 
higher treatment burden, particularly oral corticosteroids, [4].  
 
The US Food and Drug Administration (FDA) published recommendations for 
validating Patient Reported Outcome Measures (PROMs) in 2009 [5]. The FDA 
recommends a stepwise process of validation where firstly content validity is 
established by documented qualitative research and secondly construct and other 
validity is established through quantitative methods. 
 
The three most commonly used asthma specific health related quality of life 
(HRQoL) scales [6, 7, 8] were published prior to the FDA’s 2009 guidelines and 
include symptom items that are perceived negatively in this context by patients [9]. 
Additionally, these and other published asthma scales fail to assess quality of life 
deficits specific to severe asthma [10]. Thus, although existing scales are valid in 
terms of earlier definitions of validity [11, 12] or for mild and moderate asthma, they 
are not valid in terms of the FDA’s 2009 guidelines when used in people with severe 
asthma.  
 
The qualitative stage of the development and content validation of the severe 
asthma questionnaire (SAQ) has been reported in two studies [10,13]. The first study 
[10] showed that in addition to deficits experienced in mild and moderate asthma, 
those with severe asthma had additional problems in their lives primarily caused by 
two factors. First, the side effects of medication produced a variety of problems 
including mood changes, changes in self-perception, problems with eating, sleep 
disturbance, and appearance.  Second, exacerbations (in particular those leading to 
hospitalisation) created problems for the patient and the wider family. 
 
Using our findings from the first study we drafted a severe asthma specific 
questionnaire, and subsequently conducted four focus groups in which patients with 
severe asthma provided iterative changes to the design and content of the draft 
questionnaire [13]. The aim of this second phase was to ensure that the 
questionnaire was able to correctly capture the kind of information patients felt 
important in relation to their quality of life. Patients defined the response scale, 
combined two items, split one item to assess different impacts on family lives, 
advised on recall period and optimised the wording of individual items. In addition, 
patients expressed a desire to provide an overall assessment of their quality of life 
(see the online supplement, Figure E1).  
 
The SAQ comprises 16 questions about different aspects of life and a global 
question that assesses their quality of life overall.  The SMOG grade [14] for the 
SAQ is 5.9, indicating suitability for a reading age of at least 11-12 years. The 
unweighted aggregation of the 16 questions produces a score similar in methodology 
with other quality of life questionnaires. The additional global question is used for two 
 
reasons.  First, patients express a strong preference for providing an overall score in 
contrast to those requiring a differentiation between different aspects of life.  The 
second reason is psychological.  Patients make judgements, including judgements 
about their lives, using either one or a combination of two cognitive processes, called 
System 1 and System 2.  System 1 judgements are fast, automatic and the process 
unavailable to consciousness.  System 2 judgements are slow, deliberative, and 
people can introspect the process [15]. A patient’s response to a question in clinic 
‘how are you?’ will be influenced primarily by a System 1 judgement.  The use of two 
types of measure, the SAQ score based on the 16 items and the SAQ global score 
provides a way of capturing these different kinds of judgement [16]. Single item 
scales are less preferred in clinical trials because the use of multiple items reduces 
error variance. 
 
The aim of this study was to provide the final stage of validation required by the FDA, 
namely a quantitative study that establishes construct and other types of validity. 
 
Method  
Participants 
Patients diagnosed with severe asthma as defined by the international consensus 
statement from the European Respiratory and American Thoracic Societies [1] aged 
≥16 years of age who attended the Plymouth severe asthma service were invited to 
participate. Those with significant other conditions contributing to their respiratory 
symptoms, e.g. lung cancer, heart failure or severe COPD were excluded.  
 
  
 
Questionnaires 
 
Severe Asthma Questionnaire (SAQ) comprises 16 items, with response options on 
a 7-point scale averaged to produce the SAQ score (scores 1 – 7) and a 100-point 
Borg-type scale [17] producing the SAQ-global score (scores 0 – 100). Quantifiers 
are indicated against all seven of the SAQ response options. A Borg scale is a 
category rating scale with quantifiers at either end and additional, empirically placed 
quantifiers along the categories of the scale.  The SAQ-global was adapted from an 
existing global quality of life scale [18] see www.saq.org.uk. 
 
Mini Asthma Quality of Life Questionnaire (MiniAQLQ) [7] comprises 15 items with 
response options on a 7-point scale with responses averaged (scores 1-7). 
 
Asthma Control Test (ACT) comprises five symptom and medication items (5 
response options per item) totalled to produce an asthma control score. [19]. 
 
EQ-5D-5L comprises five quality of life items (5 response options per item) which 
were averaged to produce an EQ-5D-5L score and the   
EQ5D-VAS. A 100-point visual analogue scale (scores 1 – 100) [20]. 
 
Criteria for missing data are shown in the online supplement. 
Clinic data  
Clinic data collected were: spirometry (FEV1), prednisolone dose (mg/day), number 
of severe exacerbations in the last 12 months requiring systemic steroids, Global 
 
Initiative for Asthma (GINA) severity, BMI, estimated cumulative oral corticosteroid 
(OCS) dose per year. This was calculated by multiplying the participant’s 
maintenance steroid dose by 365 days, and adding an estimate of OCS use per 
exacerbation in the previous 12 months. Based on British Thoracic Society and 
GINA guidance one exacerbation was judged to comprise prednisolone 40mg/day 
multiplied by 7 days which equates to 280mg of prednisolone per exacerbation 
[21,22]. 
 
Procedure 
Patients were recruited to the validation study or the reliability study or both studies. 
Questionnaires were completed either at home (postal return of questionnaire) or in 
clinic.  Participants’ data were included in the analysis of test re-test reliability if their 
ACT scores did not change by the Minimum Clinically Important Difference (MCID) of 
3 points or more and they reported stable asthma (see online supplement, Figure 
E2). 
 
Analysis 
Analysis was on an intention to treat basis (see online supplement, Figure E2). 
Convergent validity between questionnaires was established using Pearson 
correlations. Groups of patients were identified by (a) level of maintenance dose of 
OCS (mg/day) and (b) estimated cumulative OCS dose per year. Differences 
between groups (discriminant validity) were tested by one-way analysis of variance 
(ANOVA) and where significant followed by Least Significant Difference (LSD) post 
hoc tests. Construct validity was tested by exploratory factor analysis using principal 
axis factoring following recommended practice [23, 24]. Evidence that the items 
 
could be aggregated into a single scale score was tested by examining whether the 
scree test indicated a unifactorial solution and whether items loaded significantly (> 
0.3) on the first factor.  Test-retest reliability was calculated by intra-class 
correlations. Internal consistency was calculated by Cronbach’s alpha coefficient. All 
analysis was conducted using IBM SPSS statistics 24. 
 
Ethical approval 
The study was approved by the Plymouth Hospitals NHS Trust and REC/HRA, 
ethical approval number 16/NE/0188, IRAS ID: 207601.  All patients provided 
informed written consent. 
 
Results 
 
Questionnaire completion and return.  
 
For the validation study 260 participants were invited to participate, 20 declined to 
participate, 54 failed to return questionnaires by post, and 26 patients failed to attend 
their clinic appointment and provide written informed consent leaving 160 
participants. For the test-retest reliability study 115 patients were invited to 
participate, 10 declined. Of the 105 who consented for the test-retest reliability study, 
returned questionnaires were received from 67 patients, and 16 patients were 
excluded because their ACT score had changed by 3 points or more leaving 51 
participants (37 female). (See online supplement, Figure E2). One patient at GINA 
step 2 was recruited although they did not meet the criteria for severe asthma they 
were at higher risk and enrolled in the study in error. Their data has been included in 
 
the analysis as this studied used intention to treat criteria. Participant demographics 
are displayed in Table 1. 
 
Of the 160 patients who participated in the validation study, completed 
questionnaires were as follows: SAQ (154/96% completed), MiniAQLQ (146/91% 
completed), ACT (159/99% completed). One hundred participants were asked to 
complete the EQ-5D-5L (96/96% completed).  
 
Table 2 shows the correlations between the different questionnaires.  All correlations 
were above 0.60, showing convergence between the different questionnaires. In 
addition, the correlations between all questionnaires, BMI and FEV1 percent 
predicted are also shown. 
 
Table 3 shows the mean, range, and standard deviation of responses to the 16 items 
of the SAQ. Absence of floor or ceiling effects is indicated by no SAQ item having a 
standard deviation less than one point away from an end point. In addition, for all 
items participants used the full range of response options with some using every 
option between 1 and some 7 for all items (see Table E1 in the online supplement). 
These results show that no item should be rejected on the basis of poor distribution.  
The SAQ scores ranged from 5 (extremely bad quality of life) to 100 (perfect quality 
of life) (see Table E3 in the online supplement). 
 
To test whether it is valid to aggregate the 16 items into a single scale score, 
exploratory factor analysis of the SAQ revealed a one factor solution using the scree 
 
test (the first four eigenvalues were 9.91, 1.11, 0.92, 0.72,) accounting for 60% of the 
variance. The factor scores are shown in Table 3. All factor scores are above 0.6 
showing that despite difference in content all items were related to the same latent 
variable. Cronach’s alpha coefficient was 0.96. Test-retest reliability as measured by 
intra-class correlation was 0.93 (CI 0.87-0.96) for the SAQ and 0.93 (CI 0.86-0.96) 
for the SAQ-global, showing that the SAQ is a reliable scale. Test-retest reliability 
was also calculated individually for each item of the SAQ (see Table E3 in the online 
supplement). 
 
Table 4 shows the mean and standard deviation score values for each of the six 
scales as a function of four groups of patients: no maintenance prednisolone, 1-9mg 
per day, 10 mg per day, and >10mg per day (ranges were selected to achieve 
groups of approximately equal size). All scales were significantly different across the 
four groups p<0.001, showing that the SAQ can discriminate between groups that 
are theoretically predicted to be different based on asthma severity. To compare the 
discrimination of different questionnaires between the 10mg/day and >10mg/day 
groups as a function of maintenance dose, we conducted LSD tests. Significant 
differences were found for the SAQ score (p =0.01), SAQ-global score (p=0.01) and 
EQ5D-VAS score (p=0.02), but not the MiniAQLQ score (p=0.13) nor the ACT score 
(p=0.34) nor EQ-5D-5L score (p=0.23).  With regard to other paired comparisons, 
there is pattern of poorer outcome with increasing dose of OCS except for the 
comparison between those on no maintenance OCS versus those on between 1 – 
9mg.  For these comparisons (using LSD tests), the 1 – 9mg dose had better quality 
of life than the no maintenance dose for the MiniAQLQ (p=0.008), the ACT 
(p=0.001), the SAQ (p = 0.017) but not the SAQ-global (p=0.19), the EQ-5D-5L 
 
(p=0.2), or the EQ5D-VAS (p=0.4). Because the 1 – 9mg dose group had better 
quality of life than the no maintenance dose group, we examined possible 
differences in biologic prescription between the four groups.  In the zero dose group, 
17/101 (17%) were on biologics whereas the figures for the other three groups were 
1 – 9mg = 9/17 (53%), 10mg = 6/20 (30%), > 10mg = 6/22 (27%). Figure 1 provides 
a visual comparison of the SAQ and MiniAQLQ as a function of maintenance 
prednisolone dose.   
 
Participants were allocated to estimated annual cumulative OCS dose groups: (a) 0 
– 1119mg/year, (b) those on 1120-1460mg/year, (c) those on 1461-3650mg/year, (d) 
those on 3651-6595mg/year and (e) >6595mg/year. These doses were chosen to be 
clinically relevant, e.g. 1120mg/year ≈ 4 courses of OCS, 3650mg/year ≈ 10mg/day 
prednisolone, > 6595 ≈ 20mg/day prednisolone. Table 5 shows the mean scores for 
these five groups for each of the six scales. Figure 2 provides a comparison of the 
SAQ and MiniAQLQ mean scores at different doses of prednisolone. 
 
One-way ANOVA showed that there was a significant difference (p<0.001) between 
the five estimated cumulative OCS dose groups for all questionnaires. In order to 
carry out post hoc tests that are equivalent to those of Table 4, we combined the two 
groups with the highest burden, namely those on 3651-6595mg/year and those on 
>6595 mg/year. ANOVA was repeated on the four groups (all questionnaires were 
significant at p<0.001). Significant differences were found between those on 1461-
3650mg/year, and >3650 mg/year for the SAQ score (p>0.001), MiniAQLQ score 
(p>0.01), ACT total (p = 0.004), EQ-5D-5L score (p=0.003) and the SAQ-global 
score (p=0.006) and the EQ5D-VAS (p=0.04).  
 
 
Discussion 
The FDA’s guidance for valid questionnaire construction [5] requires documentation 
of a qualitative stage of research followed by a quantitative stage. The SAQ was 
developed on the basis of qualitative research reported elsewhere [10, 13]. In this 
paper we provide details of the quantitative stage. 
 
People with severe asthma experience difficulty in a number of different domains of 
life experience, some of which are not experienced by those with mild and moderate 
asthma.  For example, 28% felt that irritability, a side effect of OCS, made life either 
very difficult or very, very difficult, and 27% experienced this level of difficulty with 
food.  Thirty nine percent reported that ‘problems at night’ made life at least very 
difficult, where sleep disturbance can be caused either by asthma symptoms (which 
cause waking) or the side effects of OCS (which cause sleep difficulty getting to 
sleep, waking and additional problems during the night).  Two family items are 
included in the SAQ as a result of the earlier qualitative research [13].  Twenty 
percent of patients rated their family lives as at least very difficult for themselves, and 
18% rated it at least very difficult for other family members, confirming the earlier 
qualitative research that severe asthma impacts family life not only for the patient but 
also the patient’s family.  These descriptive results show that people with severe 
asthma can experience non-trivial disutility in domains of experience which are not 
included in questionnaires designed for mild and moderate asthma, with particularly 
high disutility recorded for ‘the way I look’, ‘getting tired’   and the two items 
assessing different worries about medication. 
 
 
Although some people with severe asthma experience very poor quality of life, this is 
not a universal experience. For example, although 32% of people in this study felt 
they had moderately bad quality of life or worse, 24% felt they had good quality of life 
or better.  Although some of this difference can be explained by severity and 
treatment differences (those with greater OCS burden report poorer quality of life) 
the relationship between severity, treatment and quality of life is complex. 
 
In addition to providing descriptive data on people with severe asthma, the data 
provide construct validity for the SAQ. Statistical analysis showed that all 16 items 
could be aggregated into a single score and that no item should be rejected on 
purely statistical groups. The intra-class test-retest reliability of the SAQ and SAQ-
global of 0.93 compares well with other questionnaires e.g. the MiniAQLQ of 0.83 [7]. 
The SAQ score and the SAQ-global score correlate with other asthma and generic 
scales thereby providing convergent validity. The SAQ score discriminates between 
groups of patients defined by maintenance prednisolone dose and defined by 
estimated cumulative OCS burden per year, thereby providing discriminant validity.  
There is a trend for the SAQ to demonstrate greater QoL impairment with increasing 
OCS burden compared to the MiniAQLQ but the study is underpowered to make 
statistical comparisons between scales. 
 
All outcome measures showed a trend towards poorer quality of life with greater 
doses of OCS, except for the comparison between those on no prednisolone versus 
those prescribed between 1 and 9mg per day.  We do not know why the 1 – 9mg 
group had better quality of life than those without a maintenance dose, but it may be 
due to the higher use of biologics in the 1 – 9mg group. Further studies are needed 
 
to clarify the complex relationship between biologics and OCS on quality of life 
versus asthma symptoms [25].  
 
The SAQ differs from other asthma-specific scales in that it includes a single item 
100-point scale of global quality of life, the SAQ-global, which is included due to 
patient request. In this respect the SAQ is similar to the EQ5D where there is also a 
single item 100-point scale, the EQ5D-VAS.  The SAQ-global is a 0-100 Borg type 
scale adapted from another scale [18], and research shows the use of additional 
quantifiers is more reliable than the format used in the EQ5D-VAS [15] where only 
the end points have quantifiers. With the exception of the EQ5D and EQ5D-VAS, all 
questionnaires show weak to moderate correlations with lung function indicating that 
lung function plays a modest causal effect on these measures.  The absence of a 
significant correlation for the EQ5D and EQ5D-VAS suggests that these two 
measures may not be valid for assessing the quality of life of severe asthma.   
 
Multiple item scales often have better reliability than single item scales for statistical 
reasons. Consistent with other research showing Borg scales to be more reliable 
than visual analogue scales [18], our data show that the SAQ-global is highly reliable 
and as reliable as the SAQ score. The SAQ-global also correlates well with other 
scales. Comparison between the EQ5D and EQ5D-VAS suggests that the EQ5D-
VAS measures a broader concept than the EQ5D [16], and the same difference may 
apply to the SAQ score and SAQ-global. Additionally, response to these two different 
parts of the SAQ may reflect different cognitive processes – a fast automatic process 
for the SAQ-global and a slow deliberate process for the SAQ score [15]. Our study 
shows that ratings of ‘Good quality of life’ on the SAQ-global (i.e., those in the 70-79 
 
range) equates to ‘makes my life slightly difficult’ (i.e. a mean score of 4.8 on the 
SAQ – see Table E3 in the online supplement), showing that the way a question is 
asked affects the patient’s response. Both types of measure can be useful, but it is 
likely that the SAQ-global provides a value more consistent with patients’ immediate 
response when clinicians ask about their asthma. 
 
Limitations  
The estimated cumulative OCS dose might be underestimate of OCS burden as 
patients with severe asthma may often require a longer course of OCS for an 
exacerbation than the 7 days used in our calculation. Use of biologics were not 
considered in this analysis and may affect quality of life assessments.  The study 
was carried out in the South West of the UK, and although the study population is 
not dissimilar to the UK demographic data presented within the UK severe asthma 
registry [26], the population was predominantly Caucasian and further validation in 
ethnically and culturally diverse populations is required.  The literacy level required to 
use the SAQ is at least age 11-12 years old reading level, but this is consistent with 
current literacy requirements for patient communication [27].  The 15-item MiniAQLQ 
rather than the 32-item AQLQ was used as a comparison scale to reduce 
questionnaire fatigue and because the MiniAQLQ is similar in length the SAQ. Nine 
patients participating in this study also participated in an earlier qualitative work [13].  
 
.The SAQ is structured so that the global measure appears after the 16 contest 
specific items, and this order of presentation may have an effect.  Research shows 
that prior exposure to a negative event (i.e., asking patients about difficulty in 
different contexts), will lead to a more positive subsequent judgement [28,29]. 
 
Further research is needed to explore how contextual factors, including the order of 
presentation of different questions influences quality of life judgements. 
 
Conclusions 
The SAQ was designed to detect the impact of both asthma symptoms and 
treatment on quality of life and has been shown to be content valid in earlier studies 
[10, 13].  This paper confirms the relevance of items based on the earlier studies, 
establishes the construct validity of the scale and shows it to be a reliable in a group 
of patients with severe asthma with different types of treatment.  These data 
complete the validation procedures required by the FDA. Longitudinal studies are 
required to provide further information about the scale, for example, to establish 
sensitivity to change and the minimally clinically important difference in people with 
severe asthma. The SAQ is available for use in the British English version reported 
here and is available from the authors or online (www.saq.org.uk). Translations in 
other languages are required.  In addition to providing a scale that is fit for purpose 
[10] for assessing health related quality of life in clinical trials, the SAQ can also be 
used in clinical practice to alert clinicians to the problems experienced by patients, 
and to gain an initial insight into the patients’ own perceptions of the impact of illness 
and its treatment on their lives. 
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Figure 1. Mean SAQ and MiniAQLQ scores as a function of maintenance 
prednisolone dose (mg/day). When comparing 10mg to >10mg/day of maintenance 
prednisolone use, the SAQ detects a statistically significant difference in mean 
questionnaire score, but the mini-AQLQ does not. 
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Figure 2. Mean SAQ and MiniAQLQ scores as a function of estimated annual 
cumulative OCS dose.  
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Table 1. 
Demographic information for all patients, those at GINA step 4 and step 5 of 
treatment. 
 All 
(N=160)* 
GINA Step 4 
(N=100) 
GINA Step 5 
(N=59) 
Female (%) 107 (66) 67 (67) 40 (67) 
Age (range) 51 (16-78) 49 (16-74) 55 (25-78) 
FEV1 (Litres) (range) 2.0 (0.7 - 4.4) 2.2 (0.72-4.3) 1.8 (0.7-3.6) 
FEV1 (% predicted) 
(range) 
72 (28 - 137) 75 (28-137) 65 (34-107) 
Caucasian (%) 98 - - 
BMI (range) 31.8 (18.2-58.3) 31.0 
(19.0 -58.3) 
33.3 (20.7-57.9) 
Median ICS dose (BDP 
equivalent mcg/d) (range) 
1600 (400-4000) 1600 (800-
4000) 
2000 (1000-
4000) 
Number on Biologics   
Omalizumab 34 (21%)   
Mepolizumab 4 (3%)   
 
*One patient at GINA step 2 was included erroneously but included in the intention to 
treat analysis, see results section  
 
Table 2. Pearsons’ correlations between all six scales, BMI and FEV1 percent 
predicted (n)  
 SAQ-
score 
 
MiniAQLQ-
score 
ACT-
total 
EQ-5D-
5L 
score 
 
EQ5D-
VAS 
 
SAQ 
global 
score 
MiniAQLQ-
score 
0.76*** 
(140) 
- - - - - 
ACT-total 0.68*** 
(154) 
0.84*** 
(145) 
- - - - 
EQ-5D-5L 
score 
-0.76*** 
(97) 
-0.72*** 
(99) 
-0.67*** 
(100) 
- - - 
EQ5D- VAS 0.71*** 
(96) 
0.76*** 
(98) 
0.66*** 
(99) 
-0.79*** 
(98) 
- - 
SAQ global 
scale 
0.72*** 
(158) 
0.71*** 
(140) 
0.68*** 
(154) 
-0.71*** 
(97) 
0.76*** 
(97) 
- 
BMI -0.31*** 
(154) 
-0.25** 
(146) 
-0.25** 
(159) 
0.44*** 
(100) 
-0.24* 
(100) 
-0.22** 
(154) 
FEV1 percent 
predicted 
 
0.27** 
(154) 
0.30*** 
(146) 
0.24** 
(159) 
-0.13 
(100) 
0.16 
(100) 
0.26** 
(154) 
*p<0.05, **p<0.01, ***p<0.001 
  
 
Table 3. 
Mean, Standard Deviation, factor loadings, and the percentage of participants 
responding ‘very difficult’ or ‘very, very difficult’ to each of the 16 items of the Severe 
Asthma Questionnaire 
Item Mean* 
Standard 
Deviation 
Percentage 
of patients 
responding 
‘very 
difficult’ or 
‘very, very 
difficult’ 
Factor 
loading 
1. My social life. For example: visiting 
friends, walking with friends, talking with 
friends, going to bars/restaurants, and 
parties. 
4.11 1.94 25.2% 0.88 
2. My personal life. For example: 
washing, dressing, looking after myself, 
love life. 
4.98 1.98 15.0% 0.81 
3. My leisure activities. For example: 
walking for pleasure, sports, exercise, 
travelling, taking vacations. 
3.54 1.95 37.5% 0.84 
4. My jobs around the house. For 
example: housework, shopping, home 
maintenance, gardening. 
3.96 1.92 27.2% 0.88 
5. My work or education. For example, 
missing days, can’t do all I want to do. 
4.78 2.64 25.7% 0.6 
6. My family life – how it affects me. For 
example: caring for children, family 
responsibilities 
4.59 2 19.6% 0.87 
7. My family life – how it affects others. 
For example: others taking time off work, 
problems with childcare, family members 
becoming upset. 
4.74 2.1 18.3% 0.82 
8. Depression. For example, feeling sad, 
fed up, blue. 
 
4.05 1.98 29.0% 0.81 
9. Irritable. For example, snap at people, 
get angrier than I should. 
4.06 1.99 27.8% 0.77 
10. Anxiety in general. For example, 
worry about things, always on edge. 
4.03 2.1 29.7% 0.75 
 
11. Worry that asthma may get worse. 
For example, medicines no longer help, 
more frequent attacks. 
3.7 2.04 39.2% 0.71 
12. Worry about long term side effects of 
medicines. For example, worry about 
cataracts, diabetes, bone fracture. 
3.92 2.12 33.8% 0.66 
13. Getting tired. For example, feeling 
tired for no reason, waking in the 
morning feeling tired. 
3.16 1.9 43.3% 0.79 
14. Problems at night. For example, 
difficulty going to sleep, being woken 
very easily, waking often at night. 
3.5 1.99 39.2% 0.79 
15. The way I look. For example, my 
weight, my skin bruises easily, using 
medicines in public, other people judging 
me 
3.65 2.17 39.9% 0.68 
16. Problems with food. For example, I 
find I get very hungry, I just can’t stop 
eating, stomach problems (e.g., pain, 
bloating, etc.) 
4.27 2.07 26.8% 0.67 
* Interpretation of mean: In relation to quality of life, 1 = very, very difficult (worst 
possible); 2 = very difficult; 3 = difficult; 4 = moderately difficult; 5 = slightly difficult; 6 
= very slightly difficult (just noticeable); 7 = no problem. 
 
  
 
Table 4. 
Mean, confidence intervals and n-values questionnaire scores and n at different 
levels of prednisolone dose  
Maintenance prednisolone dose ranges (mg/day) 
 0 1-9 10 >10 
SAQ-score 4.23 
3.93-4.54 
99 
5.18 
4.55-5.81 
16 
3.67 
2.96-4.40 
18 
2.45 
1.90-3.00 
21 
MiniAQLQ-
score 
4.20            
3.90-4.49 
92 
5.21                
4.54-5.89 
16 
3.57                    
2.82-4.31                          
18 
2.89                    
2.24-3.52               
20 
 
ACT-total 
 
14.36          
13.28-15.43 
101 
19.63            
16.48-22.77 
16 
12.00                            
9.31-14.69             
20 
10.36                 
7.94-12.78 
22 
EQ-5D-5L 
score 
 
2.01            
1.79-2.23 
60 
1.69                
1.24-2.14 
15 
2.69                     
2.14-3.23 
13 
3.11                    
2.48-3.75 
12 
EQ-5D-VAS 65.40         
59.67-71.13 
60 
70.47            
62.46-78.47 
15 
55.77               
45.37-66.15 
13 
35.67                     
17.07-54.26 
12 
SAQ-global 
score 
58.92                  
55.18-63.50 
97 
66.38            
59.68-75.26 
17 
51                      
41.44-60.56 
20 
34.05              
22.88-45.21 
21 
Note: a lower score for the SAQ-score, MiniAQLQ, ACT total, EQ5D-VAS and SAQ-
Global score indicates low quality of life/health. A high score for the EQ-5D-5L score 
indicates poor health. 
  
 
Table 5. 
Mean, confidence intervals and n-values questionnaire scores and n at different 
doses of estimated cumulative OCS . 
Estimated annual cumulative dose (mg/year) 
 0-1119 1120-1460 1461-3650 3651-6595 >6595 
SAQ-score 4.52 
4.18- 4.85 
77 
4.20 
3.49-4.91 
21 
4.29 
3.56-5.02 
20 
3.03 
2.52-3.55 
21 
2.29 
1.60-2.99 
15 
MiniAQLQ-score 4.45 
4.13-4.76 
71 
4.32 
3.60-5.03 
22 
4.33 
3.48-5.17 
18 
3.24 
2.63-3.85 
20 
2.65 
1.99-3.10 
15 
ACT-total 15.19 
13.99-16.39 
79 
16.14 
13.35-18.94 
21 
14.62 
11.27-17.97 
21 
11.14 
8.87-13.40 
22 
8.81 
6.84 -10.79 
16 
EQ-5D-5L score 1.89 
1.64-2.15 
46 
2.02 
1.59-2.46 
17 
2.03 
1.49-2.57 
13 
2.67 
2.17-3.17 
15 
3.40 
2.81-3.99 
9 
EQ5D-VAS 66.85 
60.33-73.38 
48 
71.67 
63.38-79.95 
15 
60.15 
47.34-72.97 
13 
57.67 
48.86-66.48 
15 
22.56 
7.97-37.14 
9 
SAQ-global score 61.45 
56.90-66.01 
75 
62.76 
54.15-71.37 
21 
54.52 
44.37-64.67 
21 
47.95 
38.78-57.12 
22 
25.67 
15.64-35.70 
15 
Note: a lower score for the SAQ, MiniAQLQ, ACT total, EQ5D-VAS and SAQ-Global 
score indicates low quality of life/health. A high score for the EQ-5D-5L score 
indicates poor health. 
 
 
Online Supplementary Data 
Content validity of the Severe Asthma Questionnaire from earlier studies 
Findings of the initial patient interviews included (see [10] for more details): 
 Identification of domains that included deficits caused by symptoms of severe 
asthma as well as side effects of medication. 
 A failure of existing asthma specific quality of life scales to assess all the 
domains to severe asthma. 
Findings of the four focus groups included (see [13] for more details): 
  The recall period of two weeks was acceptable, but a two week window fails 
to reflect the patients’ desire to express the variability of severe asthma.  
Patients welcomed the ability to rate their global quality of life during the worst 
and best months of the year. 
  Patients suggested improvements to the wording of the draft questionnaire, 
including splitting some items in two (the items relating to family life), 
combining two items in one (relating to appearance and embarrassment). 
 Patients suggested changes to some of the words in individual items and the 
response scale. 
 Patients can help optimise the language of a questionnaire better if they are 
treated as partners in the process of questionnaire completion rather than 
only as a source of information. 
  
Criteria for incomplete questionnaires 
For the SAQ and MiniAQLQ, questionnaires were considered incomplete if more 
than one question was missed excluding the question on work.  In the case of the 
SAQ patients are instructed not to answer this question if not in work. In the case of 
the MiniAQLQ patients often miss this question even though they are instructed to 
answer it in terms of other activities if not in work. For the ACT a questionnaire was 
considered incomplete if one or more questions were missed. An EQ-5D-5L was 
considered incomplete if two of more questions were missed.  
 
If patients are not in work, then the SAQ score is the average of the 15 lifestyle 
questions that do not refer to work.  If patients are in work, then an extra domain is 
added because patients then have an extra domain of quality of life. Using this 
procedure, the non-work domains are the same for in and out of work patients. In the 
case of the MiniAQLQ, if patients are not in work, then they are asked to answer the 
work question in terms of other activities. Although the average MiniAQLQ score is 
obtained from the same number of questions for in work our out of work patients, the 
non-work domains no longer the same for in and out of work patients because the 
out of work patients are answering an additional non-work domain.  An aim of 
content validity is to ensure that questions are interpreted in the same way by 
different patients.  The procedure used by the SAQ achieves this aim and removes 
the inconsistency of some out of work patients completing the work item of the 
MiniAQLQ and some not doing so, which in the present study was 25 out of 160 
participants.  
  
Table E1. 
SAQ response option frequencies 
Item 1 2 3 4 5 6 7 Missing out 
 of 160 
1. My social life. For example: visiting 
friends, walking with friends, talking 
with friends, going to bars/restaurants, 
and parties. 
14 26 26 28 21 15 29 1 
2. My personal life. For example: 
washing, dressing, looking after myself, 
love life. 
6 18 21 21 18 15 61 0 
3. My leisure activities. For example: 
walking for pleasure, sports, exercise, 
travelling, taking vacations. 
25 35 31 19 17 14 19 0 
4. My jobs around the house. For 
example: housework, shopping, home 
maintenance, gardening. 
17 26 28 26 19 21 21 2 
5. My work or education. For example, 
missing days, can’t do all I want to do. 
18 18 14 18 13 13 34 32 
6. My family life – how it affects me. For 
example: caring for children, family 
responsibilities 
10 20 23 20 17 23 40 7 
7. My family life – how it affects others. 
For example: others taking time off 
work, problems with childcare, family 
members becoming upset. 
10 18 26 19 9 17 54 7 
8. Depression. For example, feeling 
sad, fed up, blue. 
16 29 23 20 23 19 25 5 
9. Irritable. For example, snap at 
people, get angrier than I should. 
17 27 23 27 16 22 26 2 
10. Anxiety in general. For example, 
worry about things, always on edge. 
23 24 27 15 16 26 27 2 
11. Worry that asthma may get worse. 
For example, medicines no longer help, 
more frequent attacks. 
21 41 23 14 21 14 24 2 
12. Worry about long term side effects 
of medicines. For example, worry about 
cataracts, diabetes, bone fracture. 
27 26 17 23 17 20 27 3 
13. Getting tired. For example, feeling 
tried for no reason, waking in the 
morning feeling tired 
38 32 32 15 15 15 11 2 
14. Problems at night. For example, 
difficulty going to sleep, being woken 
very easily, waking often at night. 
31 31 25 20 17 18 16 2 
15. The way I look. For example, my 
weight, my skin bruises easily, using 
medicines in public, other people 
judging me 
35 28 20 17 16 16 26 2 
16. Problems with food. For example, I 
find I get very hungry, I just can’t stop 
eating, stomach problems (e.g., pain, 
bloating, etc.) 
21 21 13 28 18 25 31 3 
 
 Response options: 1 = very, very difficult (worst possible); 2 = very difficult; 3 = 
difficult; 4 = moderately difficult; 5 = slightly difficult; 6 = very slightly difficult (just 
noticeable); 7 = no problem 
  
Table E2. 
Intra-class correlation, confidence intervals and n-values for the 16 items of the SAQ 
Item Intra-class 
correlation 
1. My social life. For example: visiting friends, walking with friends, talking with 
friends, going to bars/restaurants, and parties. 
0.89  
0.80-0.94 
50 
2. My personal life. For example: washing, dressing, looking after myself, love life. 0.86  
0.75-0.92 
50 
3. My leisure activities. For example: walking for pleasure, sports, exercise, 
travelling, taking vacations. 
0.93  
0.88-0.96 
51 
4. My jobs around the house. For example: housework, shopping, home 
maintenance, gardening. 
0.88  
0.79-0.93 
51 
5. My work or education. For example, missing days, can’t do all I want to do. 0.87  
0.72-0.94 
27 
6. My family life – how it affects me. For example: caring for children, family 
responsibilities 
0.89  
0.81-0.94 
46 
7. My family life – how it affects others. For example: others taking time off work, 
problems with childcare, family members becoming upset. 
0.87  
0.76-0.93 
46 
8. Depression. For example, feeling sad, fed up, blue. 0.85  
0.73-0.91 
51 
9. Irritable. For example, snap at people, get angrier than I should. 0.85  
0.74-0.91 
51 
10. Anxiety in general. For example, worry about things, always on edge. 0.84  
0.71-0.91 
51 
11. Worry that asthma may get worse. For example, medicines no longer help, 
more frequent attacks. 
0.84  
0.73-0.91 
51 
12. Worry about long term side effects of medicines. For example, worry about 
cataracts, diabetes, bone fracture. 
0.66  
0.40-0.81 
50 
13. Getting tired. For example, feeling tired for no reason, waking in the morning 
feeling tired. 
0.88  
0.78-0.93 
51 
14. Problems at night. For example, difficulty going to sleep, being woken very 
easily, waking often at night. 
0.84  
0.71-0.91 
51 
15. The way I look. For example, my weight, my skin bruises easily, using 
medicines in public, other people judging me 
0.86  
0.75-0.92 
51 
16. Problems with food. For example, I find I get very hungry, I just can’t stop 
eating, stomach problems(e.g., pain, bloating, etc.) 
0.77  
0.59-0.87 
50 
 
Table E3. Relationship between SAQ and SAQ-global scores 
SAQ-global score and 
descriptors* of quality of 
life 
Number of 
patients 
Mean SAQ 
score** (SD) 
0-9  Extremely bad 4 1.5 (0.6) 
10-19  Very bad 6 3.0 (1.9) 
20-29 Bad 10 2.0 (0.7) 
30-39  12 2.7 (1.0) 
40-49 Somewhat bad 26 3.3 (0.7) 
50-59  21 3.8 (0.8) 
60-69 Moderately good 19 4.3 (1.5) 
70-79 Good 31 4.8 (1.1) 
80-89 Very good 17 5.5 (1.6) 
90-100 Nearly 
perfect/Perfect 
8 6.4 (0.9) 
 
*The position of descriptors is approximate in relation to numbers. The exact position is 
shown in the SAQ. 
** Interpretation of mean: 1 = very, very difficult (worst possible); 2 = very difficult; 3 = 
difficult; 4 = moderately difficult; 5 = slightly difficult; 6 = very slightly difficult (just 
noticeable); 7 = no problem 
 
